Keep up-to-date with the LATEST news and publications on
routine HIV testing in the United States
since the 2008
National Summit on HIV Diagnosis, Prevention, and Access to Care.
The Forum for Collaborative HIV Research would like
to congratulate Executive Committee Members Cornelius Baker and Michael Horberg, MD on their appointment to the
Presidential Advisory Council on HIV/AIDS.Health and Human Services Secretary Kathleen Sebelius announced their
appointment on February 1, 2010.
The Forum for Collaborative HIV Research would like
to congratulate Executive Committee Members Cornelius Baker and Michael Horberg, MD on their appointment to the
Presidential Advisory Council on HIV/AIDS.Health and Human Services Secretary Kathleen Sebelius announced their
appointment on February 1, 2010.
On Tuesday, September 29, 2009, the Kaiser
Family Foundation held a live, interactive webcast from its Washington, D.C., studio
featuring an expert panel discussing the U.S. strategy for combating the
global tuberculosis (TB) epidemic.Click here to view.
Recognizing the need for education
regarding HCV drug resistance, the Forum for Collaborative HIV Research's HCV
Drug Development Advisory Group (academicians, clinicians, researchers and
patient advocates) have contributed to a slide deck explaining resistance in
HCV, its consequences as well as its mitigation.
The 2010 National Summit on HIV Diagnosis, Prevention, and Access to Care (November 17-20, 2010, National Harbor, MD) is sponsored by the Forum for Collaborative HIV Research.
HIV Diagnostic and Monitoring Technologies in Resource Limited Settings
An update meeting to the Pediatric Diagnostic and Monitoring
Technologies Meeting in 2006 as well as adult treatment and monitoring
technologies was held in a roundtable format.
HEP DART 2009, Frontiers in Drug Development for Viral Hepatitis Education Round-Table
An education roundtable will be at held the upcoming HEP DART meeting in
Hawaii On Tuesday, December 8, 2009 to educate Hepatitis C virus
infected patients and update physicians who treat them about risk for,
and avoidance of drug resistance to the next generation of HCV antiviral
therapies.
IV. HCV Drug Resistance Advisory Group, November 2009
The Fourth HCV Drug Resistance Advisory Group (HCV DRAG) meeting was held to discuss HCV drug resistance issues for directly acting antivirals in clinical trials.
Consultation on the Inclusion of Adolescents in HIV Biomedical Prevention Clinical Trials
In collaboration with Eunice Kennedy Shriver National Institute of Child
Health and Human Development, the National Institute of Mental Health, National
Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases,
and the Office of AIDS Research. This consultation will focus on examining and
discussing the desirability and timing of as well as barriers to enrollment of
adolescents in these trials. Participants will include representatives
from academia, industry, HIV-affected communities, and various branches of the United States
government. These participants will offer an expanse of expertise
covering the medical, behavioral, ethical, legal and regulatory ramifications
of including or not including adolescents in biomedical prevention trials.
Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.
Following discussions that took place
at the 2008 HIV Summit,
a roundtable on "Metrics and Evaluation Measures for Monitoring the
Implementation of Routine HIV Testing in the U.S." was held to bring
together a panel to discuss the metrics needed
to assess expansion of HIV testing and efforts to link individuals to
care since
the 2006 CDC recommendations for HIV testing for adults, adolescents
and
pregnant women in health-care settings.
Implementing Routine HIV Testing in Correctional Facilities: Challenges and Opportunities
Continuing the series on maximizing opportunities
for HIV diagnosis and access to care, the Forum for Collaborative HIV Research
hosted a roundtable discussion on April 27, 2009, focusing on identifying and
discussing the challenges associated with the implementation of routine HIV
testing in correctional settings in the United States.
III. HCV Drug Resistance Advisory Group, March 2009
The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
The 2008 National Summit on HIV Diagnosis, Prevention, and Access to Care (November 19-21, 2008, Arlington, VA) is sponsored by the Forum for Collaborative HIV Research in partnership with the American Academy of HIV Medicine, Centers for Disease Control and Prevention, HIV Medicine Association, Human Resources and Services Administration, Kaiser Permanente, National Black Gay Men's Advocacy Coalition, the Office of AIDS Research-NIH, and the Veterans Administration.
The 2010 National Summit on HIV Diagnosis, Prevention, and Access to Care (November 17-20, 2010, National Harbor, MD) is sponsored by the Forum for Collaborative HIV Research.
The 2008 National Summit on HIV Diagnosis, Prevention, and Access to Care (November 19-21, 2008, Arlington, VA) is sponsored by the Forum for Collaborative HIV Research in partnership with the American Academy of HIV Medicine, Centers for Disease Control and Prevention, HIV Medicine Association, Human Resources and Services Administration, Kaiser Permanente, National Black Gay Men's Advocacy Coalition, the Office of AIDS Research-NIH, and the Veterans Administration.